GENRIX BIO

Chongqing Genrix Biopharmaceutical Co., Ltd. (referred to as GENRIX BIO) was established in 2015. Adhering to the core values of "social benefits first, corporate benefits second," it focuses on the research, development, and industrialization of novel monoclonal antibody drugs, concentrating on three major therapeutic areas: autoimmune diseases, infectious diseases, and cancer. The company has established R&D subsidiaries and offices in Beijing, Shanghai, Hefei, and other places, with nearly 400 employees. The company adheres to a dual-driven development strategy of innovation and quality, continuously providing patients with reliable and affordable innovative biologics.